254 related articles for article (PubMed ID: 28229177)
1. Advanced Glycation End Product 3 (AGE3) Increases Apoptosis and the Expression of Sclerostin by Stimulating TGF-β Expression and Secretion in Osteocyte-Like MLO-Y4-A2 Cells.
Notsu M; Kanazawa I; Takeno A; Yokomoto-Umakoshi M; Tanaka KI; Yamaguchi T; Sugimoto T
Calcif Tissue Int; 2017 Apr; 100(4):402-411. PubMed ID: 28229177
[TBL] [Abstract][Full Text] [Related]
2. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells.
Tanaka K; Yamaguchi T; Kanazawa I; Sugimoto T
Biochem Biophys Res Commun; 2015 May; 461(2):193-9. PubMed ID: 25721666
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by increasing TGF-β expression and secretion.
Notsu M; Yamaguchi T; Okazaki K; Tanaka K; Ogawa N; Kanazawa I; Sugimoto T
Endocrinology; 2014 Jul; 155(7):2402-10. PubMed ID: 24758301
[TBL] [Abstract][Full Text] [Related]
4. FOXO1 Mediates Advanced Glycation End Products Induced Mouse Osteocyte-Like MLO-Y4 Cell Apoptosis and Dysfunctions.
Zhang C; Wei W; Chi M; Wan Y; Li X; Qi M; Zhou Y
J Diabetes Res; 2019; 2019():6757428. PubMed ID: 31886284
[TBL] [Abstract][Full Text] [Related]
5. Iron overload induced osteocytes apoptosis and led to bone loss in Hepcidin
Ma J; Wang A; Zhang H; Liu B; Geng Y; Xu Y; Zuo G; Jia P
Bone; 2022 Nov; 164():116511. PubMed ID: 35933095
[TBL] [Abstract][Full Text] [Related]
6. Activation of AMP-activated protein kinase decreases receptor activator of NF-κB ligand expression and increases sclerostin expression by inhibiting the mevalonate pathway in osteocytic MLO-Y4 cells.
Yokomoto-Umakoshi M; Kanazawa I; Takeno A; Tanaka K; Notsu M; Sugimoto T
Biochem Biophys Res Commun; 2016 Jan; 469(4):791-6. PubMed ID: 26713363
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end products induced IL-6 and VEGF-A production and apoptosis in osteocyte-like MLO-Y4 cells by activating RAGE and ERK1/2, P38 and STAT3 signalling pathways.
Chen H; Liu W; Wu X; Gou M; Shen J; Wang H
Int Immunopharmacol; 2017 Nov; 52():143-149. PubMed ID: 28910744
[TBL] [Abstract][Full Text] [Related]
8. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
[TBL] [Abstract][Full Text] [Related]
9. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
Wu Q; Zhou X; Huang D; Ji Y; Kang F
Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
[TBL] [Abstract][Full Text] [Related]
10. Advanced glycation end-product 2 and Porphyromonas gingivalis lipopolysaccharide increase sclerostin expression in mouse osteocyte-like cells.
Sakamoto E; Kido JI; Takagi R; Inagaki Y; Naruishi K; Nagata T; Yumoto H
Bone; 2019 May; 122():22-30. PubMed ID: 30735798
[TBL] [Abstract][Full Text] [Related]
11. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ
PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin Promotes Bone Remodeling in the Process of Tooth Movement.
Shu R; Bai D; Sheu T; He Y; Yang X; Xue C; He Y; Zhao M; Han X
PLoS One; 2017; 12(1):e0167312. PubMed ID: 28081119
[TBL] [Abstract][Full Text] [Related]
13. Glucose uptake inhibition decreases expressions of receptor activator of nuclear factor-kappa B ligand (RANKL) and osteocalcin in osteocytic MLO-Y4-A2 cells.
Takeno A; Kanazawa I; Notsu M; Tanaka KI; Sugimoto T
Am J Physiol Endocrinol Metab; 2018 Feb; 314(2):E115-E123. PubMed ID: 29018002
[TBL] [Abstract][Full Text] [Related]
14. Insulin-Like Growth Factor-I Protects Against the Detrimental Effects of Advanced Glycation End Products and High Glucose in Myoblastic C2C12 Cells.
Adachi N; Kanazawa I; Tanaka KI; Takeno A; Notsu M; Tanaka S; Sugimoto T
Calcif Tissue Int; 2019 Jul; 105(1):89-96. PubMed ID: 30809689
[TBL] [Abstract][Full Text] [Related]
15. Effect of TNF-
Ohori F; Kitaura H; Marahleh A; Kishikawa A; Ogawa S; Qi J; Shen WR; Noguchi T; Nara Y; Mizoguchi I
J Immunol Res; 2019; 2019():9716758. PubMed ID: 31341915
[TBL] [Abstract][Full Text] [Related]
16. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
Zhao S; Zhang YK; Harris S; Ahuja SS; Bonewald LF
J Bone Miner Res; 2002 Nov; 17(11):2068-79. PubMed ID: 12412815
[TBL] [Abstract][Full Text] [Related]
17. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
18. Iron Overload-Induced Osteocyte Apoptosis Stimulates Osteoclast Differentiation Through Increasing Osteocytic RANKL Production In Vitro.
Yang J; Dong D; Luo X; Zhou J; Shang P; Zhang H
Calcif Tissue Int; 2020 Nov; 107(5):499-509. PubMed ID: 32995951
[TBL] [Abstract][Full Text] [Related]
19. Vibration enhances osteoclastogenesis by inducing RANKL expression via NF-κB signaling in osteocytes.
Sakamoto M; Fukunaga T; Sasaki K; Seiryu M; Yoshizawa M; Takeshita N; Takano-Yamamoto T
Bone; 2019 Jun; 123():56-66. PubMed ID: 30902792
[TBL] [Abstract][Full Text] [Related]
20. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
